Valuation: Evotec AG

Market Cap 526M 590M 491M 446M 841M 56.84B 847M 5.93B 2.31B 29.01B 2.22B 2.17B 93.25B P/E 2026 *
-2.32x
P/E 2027 * -6.88x
Enterprise Value 669M 750M 624M 567M 1.07B 72.26B 1.08B 7.53B 2.93B 36.88B 2.82B 2.76B 119B EV / Sales 2026 *
1.11x
EV / Sales 2027 * 0.95x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO - 30/04/2026
Chief Operating Officer - 30/04/2026
Director TitleAgeSince
Director/Board Member 58 18/06/2019
Director/Board Member 64 31/05/2021
Director/Board Member 59 09/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 584M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+1.32%+344.62%+753.25% 44.29B
+3.05%-1.58%+28.78%+35.46% 42.5B
+1.00%+0.22%+5.17%+113.80% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-0.89%-7.44%-11.43% 24.34B
Average +1.15%-0.59%+53.86%+131.42% 43.39B
Weighted average by Cap. +1.52%-0.84%+58.06%+140.75%

Financials

2026 *2027 *
Net sales 601M 674M 560M 509M 959M 64.87B 966M 6.76B 2.63B 33.11B 2.53B 2.47B 106B 724M 812M 675M 614M 1.16B 78.17B 1.16B 8.15B 3.17B 39.9B 3.05B 2.98B 128B
Net income -222M -249M -207M -188M -354M -23.97B -357M -2.5B -972M -12.23B -934M -914M -39.32B -48.25M -54.09M -44.95M -40.91M -77.04M -5.21B -77.61M -543M -211M -2.66B -203M -199M -8.55B
Net Debt 143M 160M 133M 121M 228M 15.42B 230M 1.61B 626M 7.87B 601M 588M 25.3B 162M 182M 151M 137M 259M 17.51B 261M 1.83B 710M 8.94B 682M 668M 28.72B
Logo Evotec AG
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA